Amarin (AMRN)
(Delayed Data from NSDQ)
$0.89 USD
+0.02 (2.68%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $0.89 0.00 (0.09%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
AMRN 0.89 +0.02(2.68%)
Will AMRN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRN
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?
Other News for AMRN
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Amarin to present research on benefits of VASCEPA/VAZKEPA
Largest borrow rate increases among liquid names
Largest borrow rate increases among liquid names
Amarin Corporation Plc’s New Competition Risk – A Cause for Worry?